Get the Stockscreener App
10.19
0.10%
-0.010
Iteos Therapeutics Inc stock is traded at $10.19, with a volume of 927.75K.
It is down -0.10% in the last 24 hours and up +0.69% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.20
Open:
$10.18
24h Volume:
927.75K
Relative Volume:
0.66
Market Cap:
$450.45M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.2349
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+0.79%
1M Performance:
+0.69%
6M Performance:
+37.52%
1Y Performance:
-41.67%
1-Day Range:
$10.18
$10.22
1-Week Range:
$10.10
$10.22
52-Week Range:
$4.80
$18.01
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.19 | 446.92M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
Published on: 2025-08-20 06:11:33 - Newser
What institutional flow reveals about iTeos Therapeutics Inc.Treasury Yields & Daily Profit Focused Screening - Newser
Using Python tools to backtest iTeos Therapeutics Inc. strategiesInsider Buying & Real-Time Buy Signal Notifications - Newser
Custom watchlist performance reports with iTeos Therapeutics Inc.Rate Hike & Risk Managed Investment Entry Signals - Newser
Historical volatility pattern of iTeos Therapeutics Inc. visualizedMarket Movers & Growth Focused Stock Pick Reports - Newser
iTeos Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Volume & Fast Moving Market Watchlists - Newser
Real time social sentiment graph for iTeos Therapeutics Inc.Weekly Volume Report & Daily Profit Focused Screening - Newser
Published on: 2025-08-19 22:05:02 - Newser
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY - GlobeNewswire
What MACD and RSI say about iTeos Therapeutics Inc.Wall Street Watch & Long-Term Investment Growth Plans - Newser
Published on: 2025-08-19 08:58:16 - Newser
iTeos Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Review & Low Volatility Stock Suggestions - Newser
Quantitative breakdown of iTeos Therapeutics Inc. recent moveTake Profit & Weekly Breakout Watchlists - Newser
What earnings revisions data tells us about iTeos Therapeutics Inc.2025 Technical Patterns & Risk Managed Investment Signals - Newser
Can iTeos Therapeutics Inc. hit a new high this monthSwing Trade & Expert Verified Stock Movement Alerts - Newser
Can momentum traders help lift iTeos Therapeutics Inc.2025 Biggest Moves & Stock Portfolio Risk Control - Newser
Reversal Confirmed iTeos Therapeutics Inc. Stock Rallies Above MATrade Entry Summary & Expert Curated Trade Ideas - 선데이타임즈
GSK and iTeos Advance Immunotherapy Study for Lung Cancer - TipRanks
Is iTeos Therapeutics Inc. the Top Chart Pick This Week2025 Winners & Losers & Verified Entry Point Signals - newsimpact.co.kr
Intrinsic Value of iTeos Therapeutics Inc. Stock: Is It Undervalued or OvervaluedEntry Point & AI Powered Buy/Sell Recommendations - Newser
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market News Updates - mustnews.co.kr
iTeos Therapeutics (ITOS.US) Boxer Capital, LLC sold 350,000 common shares worth approximately US$5.6927 million - 富途牛牛
GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications - TipRanks
Iteos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
iTeos Therapeutics Faces Challenges Amid Collaboration Termination - TipRanks
iTeos Therapeutics, Inc. SEC 10-Q Report - TradingView
Investigation into STAAR, CORZ, ITOS, and VBTX shareholder transactions. - AInvest
iTeos Therapeutics Inc. Approaches Support With Recovery in SightAlpha Driven Watchlist With Alerts Published - metal.it
iTeos Therapeutics Inc. Stock Poised for Technical ComebackFree Investment Portfolio Suggestions - beatles.ru
What makes iTeos Therapeutics Inc. stock price move sharplyDiscover undervalued opportunities early - Jammu Links News
What is iTeos Therapeutics Inc. company’s growth strategyGrow your portfolio with growth-oriented stocks - Jammu Links News
Is iTeos Therapeutics Inc. a growth stock or a value stockDiscover undervalued stocks ready to soar - Jammu Links News
What is the dividend policy of iTeos Therapeutics Inc. stockAchieve consistent double-digit returns - Jammu Links News
What catalysts could drive iTeos Therapeutics Inc. stock higher in 2025Build capital through low-risk investments - Jammu Links News
Is iTeos Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough results with expert guidance - Jammu Links News
How volatile is iTeos Therapeutics Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
Price momentum metrics for iTeos Therapeutics Inc. explainedDaily Technical Forecast for Quick Gains - Newser
What are the technical indicators suggesting about iTeos Therapeutics Inc.Wealth Building Planner With Proven Results - Jammu Links News
Halper Sadeh Investigates iTeos Therapeutics, Veritex Holdings Merger Deals. - AInvest
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionTrade Timing Strategy With Technical Data Explained - metal.it
Investigations into OLO, VBTX, ITOS, and WNS Shareholder Rights - AInvest
Reddit Investors Lose Big, Now Have Opportunity to Lead Fraud Lawsuit - AInvest
iTeos Therapeutics acquisition by Concentra Biosciences raises fiduciary duty concerns. - AInvest
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Visual trend scoring systems applied to iTeos Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
iTeos Therapeutics Inc. Added to High Probability Setup ListTriple Return Setup With Risk Control Explained - metal.it
These 10 Stocks are Winning Big - Insider Monkey
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iteos Therapeutics Inc Stock (ITOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Option Exercise |
4.30 |
43,882 |
188,693 |
43,882 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Option Exercise |
4.30 |
26,400 |
113,520 |
153,903 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Option Exercise |
4.30 |
8,400 |
36,120 |
144,303 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Sale |
10.03 |
43,882 |
440,136 |
0 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Sale |
10.02 |
43,883 |
439,708 |
0 |
| Detheux Michel | Chief Executive Officer |
Jun 09 '25 |
Sale |
10.03 |
8,400 |
84,252 |
135,903 |
| Detheux Michel | Chief Executive Officer |
Jun 10 '25 |
Sale |
10.02 |
8,400 |
84,168 |
135,903 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):